过去二十年来针对小细胞肺癌的新系统疗法的临床益处:一项横截面研究
Yuejing Chen1, Honghong Liu1, Shaohua Bai1
1Department of Pulmonary and Critical Care Medicine, Xingtai Third Hospital, Xingtai, Hebei, China.
The clinical respiratory journal
|October 30, 2024
概括
大多数小细胞肺癌 (SCLC) 系统疗法的随机对照试验 (RCT) 没有根据欧洲医学瘤学会-临床益处规模 (ESMO-MCBS) 显示有意义的临床益处. 未来的RCT需要更严格的功率计算,以改善临床益处评估.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 医疗恶性瘤是一种恶性疾病.
背景情况:
- 在全球范围内,小细胞肺癌 (SCLC) 仍然是一个高度致命的恶性瘤.
- 评估新型全身疗法的临床效用对于改善患者的治疗结果至关重要.
- 欧洲医学瘤学会-临床益处规模 (ESMO-MCBS) 提供了一个评估治疗益处的框架.
研究的目的:
- 评估SCLC新系统疗法的临床益处.
- 分析2002年至2023年间发表的随机对照试验 (RCT).
- 评估与ESMO-MCBS标准相关的试验设计和统计能力.
主要方法:
- 在PubMed系统搜索SCLC系统治疗的第3期RCT (2002-2023年).
- 使用ESMO-MCBS对治疗益处进行分级 (得分为1-5;4-5表明有意义的益处).
- 评估统计能力和试验设计特征 (例如,优越性与非劣势性,主要终点).
主要成果:
- 包括64个RCT,涉及23,683名参与者.
- 很大一部分RCT (61.3%) 的设计符合ESMO-MCBS的受益门.
- 只有27.6%的阳性RCT达到ESMO-MCBS显著临床益处的门;具有足够功率的试验更有可能显示益处.
结论:
- 大多数阳性SCLCRCT未能达到ESMO-MCBS定义的有意义的临床益处.
- 具有严格功率计算的试验设计对于准确评估新的SCLC疗法至关重要.
- 未来的研究应该专注于优化试验方法,以更好地确定临床上有益的治疗方法.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.0K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:27Tumor Immunotherapy
486
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
486